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1. Introduction  
Type 1 Diabetes mellitus (T1D) is an autoimmune disorder caused by destruction of pancreatic 
beta cells which produce insulin. Current estimates have shown that T1D affects about 0.4 to 
0.8% of the population worldwide accounting for 5-10% of all diabetes cases (Stock and 
Bluestone, 2004). It is seen as an increasing health hazard. For T1D, exogenous insulin 
administration is the most widely used treatment. However, this treatment has several 
limitations including development of secondary health complications over time. There are 
several approaches already in practice to replace the damaged beta cells in T1D. They include 
whole organ pancreas or isolated islet cell transplantation. Several novel approaches are 
currently in development such as expansion of adult beta cells and stem/progenitor cells 
which can be transformed into beta cells. This review summarizes recent progress made in 
beta cell replacement therapy for T1D. Diabetes mellitus has been known for thousands of 
years. Diabetes comes from an ancient Greek word coined by Arataeus of Cappadocia, and 
mellitus from the Latin word honey associated with sweet urine. (Medvei, 1993).  
The pathogenesis of T1D has been attributed to an autoimmune response. Currently the 
mechanism that triggers this disease is still unknown, but it seems to be a combination of 
environmental and genetic factors. T-cells in the host’s body become sensitized to protein 
that naturally occurs in the beta cells of the pancreas and the immune system begins to 
mount a specific attack leading to destruction of the islets of Langerhans. Several candidate 
proteins have been identified including GAD65, insulin, and ZnT8 (Harlan et al., 2009, 
Shapiro et al., 2003). Reducing the autoimmune effect in beta cell replacement is very 
important, but before moving onto the strategies for beta cell replacement therapy it is 
important to describe the standard therapy for T1D and how it falls short of providing for 
all the needs of diabetic patients. 
Exogenous insulin therapy continues to be the leading therapy for T1D today, but there are 
several complications associated with it. However, even intensive monitoring of blood 
glucose and injection of insulin is not enough to halt the secondary complications of 
diabetes (Harlan et al., 2009). Diabetes mellitus can decrease patients’ lifespan, especially in 
severe cases. Lowered blood sugar levels, which can result if too much insulin is 
administered, can also lead to a hypoglycemic episode (Cooke and Plotnick, 2008). These 
episodes are typified by ketoacidosis, where in an effort to find energy, the body burns fatty 
acids leading to the production of acidic ketones that can be detected by an alcoholic smell 
on the breath. Hypoglycemic episodes can lead to coma and even death, and is considered 
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the most severe side effect of diabetes. Secondary complications such as blindness, 
peripheral neuropathy, and cardiovascular complications result from destruction of 
microvasculature. Additionally, the quality of life is lower even for patients with well 
regulated blood sugar.  
There are several methods both clinical and experimental that are being developed to 
provide optimal beta cell replacement. The first type that was developed and successfully 
applied to the clinical setting was that of whole organ pancreas transplant (WOP). Next, in 
an effort to transplant only the insulin secreting portion of the pancreas, islet transplantation 
was explored and has been applied through several clinical trials. Efforts have been made to 
improve this technique by perfecting the techniques of islet isolation and 
immunosuppression; immunoisolation and xenotransplantation are also being explored. 
However, even if all donor human pancreases were effectively used, they would be 
insufficient to treat every patient eligible for transplant. This emphasizes the importance of 
current studies into beta cell regeneration from many sources including embryonic stem 
cells, and pancreatic ductal and acinar cells.  
2. Pancreas transplantation 
Transplantation of whole allogenic pancreas is an established procedure. The first clinical 
transplant of a whole vascularized pancreas was at the University of Minnesota in 1966. 
Initial results showed very poor graft survival rates; less than 5% of grafts survived after six 
months. Important advances were made in surgical technique and post-transplant 
monitoring. Because the pancreas is a very large, immunogenic organ, large doses of 
immunosuppressants are required to prevent rejection. Immunosuppression protocols had 
to be adjusted to prevent graft rejection while not being so strong as to damage the beta 
cells. However, the addition of mycophenolate mofetil and tacrolimus to regimens 
suppressing the immune system dramatically increased the success of whole pancreas 
transplant from 20% to 80% survival after one year. One important stepping stone in anti-
rejection therapy was the elimination of steroids. The addition of sirolimus, an 
immunosuppressant lacking nephrotoxic or beta cell toxic properties, along with an 
antilymphocyte antibody induction allowed the discontinuation of steroids from 
maintenance therapy. This immune therapy led to a low rejection rate of pancreas. Three 
year survival rate, defined as insulin independence, is around 80% according to the 
International Pancreas Transplant Registry (Gruessner, 2001).  
Transplanting a whole pancreas simultaneously or after a kidney transplant has provided 
significant improvement in patients. Since diabetes affects the function of the renal system, 
many patients will have a history of dialysis. Such an issue would call for a kidney 
transplant, and since this would already require a surgical procedure and 
immunosuppression, adding a pancreas transplant in a simultaneous fashion could prove 
beneficial (Humar et al., 2000). In fact, the development of secondary complications is 
attenuated by an allogenic pancreas transplant. Further, the progression of nephropathy is 
decreased from diabetic effects with the simultaneous transplant of a pancreas and kidney. 
There also appears to be improvements to the quality of life and in the damage to the 
peripheral nerve system (Venstrom et al., 2003).  
Although transplant of whole allogenic pancreases offers the above advantages, it comes 
with the serious complications associated with surgery. A study by the Univeristy of 
Pennsylvania (Frank et al., 2004) compared 30 whole pancreas and 27 isolated islet 
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transplants. This investigation showed that 7 patients (23%) required post-transplant 
surgery while only 1 islet recipient (7%) needed surgery. There was a significant difference 
in the number of patients requiring blood transfusions post-transplant from whole pancreas 
(43%) versus islet transplant (7%). The main reason that would account for the differences in 
surgical complications can be attributed to the invasiveness of the whole pancreas 
transplant versus the relatively non-invasive islet transplant, which is performed by 
percutaneous puncture and infusion into the portal vein of the liver. Thus long hospital 
stays are required of whole pancreas transplant cases whereas islet transplantation is an 
outpatient procedure leading to a lower estimated cost. Despite the lower surgical risk and 
cost of islet transplantation it has not yet achieved the duration or rate of graft success found 
in whole pancreas transplantation.  
An issue for beta cell replacement is the low number of donors compared to the number of 
eligible recipients (Matsumoto et al., 2006). In the United States, there are an estimated 7,000 
available donor pancreases, but the number of pancreases available for clinical transplant 
are much lower due to many exclusion criteria. For whole organ transplant, young donors 
(<50 years old), with low BMI are preferred. Although the islets received from young donors 
are suggested to display greater functionality, it is very difficult to effectively isolate a 
sufficient number of islets for transplant from these donors. Also, obese donor pancreases 
are associated with higher surgical complication rates. Conversely, isolations from pancreata 
from older, obese (BMI>30) donors produce higher yields of islets that are still functional 
and qualify for clinical transplant. Thus islet transplant has the ability to utilize marginally 
acceptable pancreases for clinical transplant, increasing the ability to perform beta cell 
replacement. These non-overlapping criteria for whole organ and islet isolation reinforce the 
notion that these two treatments are not competitive, but rather complementary. 
The important advances and improvements of whole organ pancreas transplant over the 
past two decades have given significant momentum to this method of beta cell replacement 
in patients with life-threatening diabetes. Although the one year rejection rate is higher at 
8% for solitary pancreas transplant in preuremic patients than the rejection rate of 2% seen 
in persons receiving simultaneous pancreas and kidney transplants, the increased success of 
the procedure still warrants its application (Gruessner, 2001). However, this treatment is still 
limited to patients with brittle diabetes experiencing uncontrolled blood glucose levels and 
hypoglycemic unawareness despite intensive insulin therapy. The risk of morbidity, the 
need to open the abdominal cavity during surgery, and the strong immunosuppressive 
regimen required for solid organ transplant substantiates a long, hard look at alternative 
methods of beta cell replacement.  
3. Islet cell transplantation 
The transplantation of pancreatic islets of Langerhans is an exciting alternative, because it 
reduces the surgical risk of complication by being less invasive (Frank et al., 2004). 
Furthermore, transplanting only the functional, insulin secreting portion of the pancreas 
reduces the risk of activating the exocrine, digestive portion of the pancreas, which could 
lead to deterioration of endocrine function.   
Islet transplantation also provides several other exciting possibilities. One such possibility is 
the ability to manipulate islets prior to implantation to protect them from the immune 
system or to attach biologically active molecules that could aid in engraftment. Beta cell 
regeneration by embryonic or adult stem cells also provides the possibility of a large 
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population of renewable insulin secreting cells, but the risk of neoplasm formation still 
remains a potential issue (Borowiak & Melton, 2009; Ricordi & Edlund, 2008).  Xenogenic, 
porcine islets could also fill the gap between beta cell supply and demand (Hering & 
Walawalkar, 2009). Each of these methods contains complicating factors that do not allow 
current application to the clinical setting, but recent advances have put them closer in reach 
than ever before. 
A comparison of the historical progress of whole organ transplant to that of islet 
transplantation would provide an objective basis to evaluate the progress of islet 
transplantation. Although whole organ treatment achieved high levels of graft survival in 
the years 1994-1997, the islet survival rate at five years has reached around fifty percent in 
2010-2011, comparable to the level of whole pancreas graft success (Rickels et al, 2011). From 
this perspective, islet transplantation is not inferior to pancreas organ transplantation, 
though it may not have reached its full potential yet. 
In the past decade since the publication of the Edmonton Protocol (Shapiro et al., 2000), 
there have been many advances in the field of islet transplantation, primarily in the area of 
islet isolation technique and immunosuppression therapy. Breakthroughs have been made 
in the area of pancreas procurement and preservation with study into ductal preservation, 
the two layer method, and the type of preservation solution used. Furthermore, there has 
been much progress in the islet isolation process by bringing standards up to cGMP 
qualifications, optimization of collagenase enzymes, and using iodixanol for continuous 
density gradient purification (Matsumoto et al., 2009). With the introduction of 
thymoglobulin at induction phase and the combination of prograf and mycophenolate 
mofitil as maintenance immunosuppressive agents, the islet transplant survival rate has 
significantly improved recently. 
3.1 Pancreas preservation and islet isolation 
The islet isolation process is fundamental to islet transplantation. The main stages in 
isolation are pancreas procurement and preservation, digestion of the organ, and 
purification of the islets. First, the pancreas is obtained from the organ procurement 
organization, prepared with certain preservation solutions and injections as described later. 
Upon arrival at the isolation facility, the pancreas is disinfected and injected with a digestion 
enzyme that degrades the pancreas and releases islets. Lastly, the mixture of pancreatic 
tissue is centrifuged with a density gradient to separate the endocrine tissue from the 
exocrine tissue. Within each of these procedures are detailed methodologies that have been 
explored to improve both islet yield and function. 
3.1.1 cGMP facility 
One major requirement for islet cell preparations and isolations is that it should be 
performed under current good manufacturing practices (cGMP). An important requirement 
of cGMP facilities is the validation and sterilization of all equipment (Garfinkel et al., 2004). 
Although initially assumed to increase the cost of establishing an islet isolation program, the 
guidelines of cGMP ensure the efforts of improving safety of islet preparations.  
Documentation of errors, corrective measures, and preventative actions minimize costs and 
provides the ability to critically evaluate the impact of certain actions. Validation of 
instruments prevents false bias readings, and validation of processes indicates whether 
assumptions about the production are correct or not (Yamamoto et al., 2009). 
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Documentation not only proves the correctness of the manufacturing, but also provides data 
for scientific reports. However, some of these requirements still can create a large amount of 
work. 
3.1.2 Pancreas preservation  
In the area of organ preservation, damage due to low oxygenation and warm ischemia are 
important hurdles to overcome. Warm ischemia is the time between the cessation of a heart 
beat in a donor’s body and when cold preservation solutions can be injected. Ischemia is the 
loss of blood circulation to an organ that consequently causes a lack of oxygen, glucose, and 
other helpful molecules in the blood. In general, warm ischemia times greater than fifteen 
minutes cause pancreases to be of marginal quality and times exceeding thirty minutes 
usually disqualifies the organ for transplantation. Significant amounts of damage are 
incurred to the pancreas and islets during warm ischemia time, but cold ischemia time 
should also be limited as much as possible. Cold ischemia time is incurred during 
procurement and transportation of the organ, and should be lower than twelve hours. In 
addition to ischemic injury, there is also the danger of hypoxic damage from low 
oxygenation conditions (Sawada et al., 2003). Following procurement, donor pancreases 
were initially preserved in University of Wisconsin solution (UW) or Histidine-
Tryptophan-Ketoglutarate solution (HTK). Although these solutions are standard for 
tissue preservation of other organs, other preservation methods were attempted to 
improve the results of islet isolation. The two layer method and ductal preservation have 
emerged as two techniques that preserve the pancreas while leading to increased islet 
yield and quality from isolation. 
The advent of perfluorocarbon as an excellent oxygen carrier led to significant 
improvements in reducing hypoxic damage. Perfluorocarbon (PFC) is a hydrocarbon 
derived chemical where all of the hydrogens of a carbon chain are replaced by fluorine 
atoms. The uniform covering of fluorines prevents polarization of the electron clouds, which 
explains the low van der Waals forces and non-polar nature of the molecule (Lamal, 2004). 
The property of PFC that makes it particularly attractive as an organ preservation and 
oxygenation solution is the capacity to dissolve large amounts of oxygen. This high 
dissolving power of PFC combined with a low oxygen binding constant, due to low 
intermolecular forces, allows PFC to release oxygen more effectively than hemoglobin (F2 
Chemicals Ltd., 2003).  
The Two-Layer Method (TLM) involves placing PFC, which is almost twice as dense as 
water, beneath the UW/HTK solution and oxygenating the solution before adding a 
procured pancreas. The addition of a water based preservation solution above the PFC 
solution prevented the loss of dissolved oxygen (Matsumoto & Kuroda, 2002). The 
distinction between the static and original TLM is that the original method provides 
continuous oxygen supplied to the PFC, while static method precharges the PFC with 
oxygen before the organ is added. Cold ischemia time for human pancreata can be extended 
up to thirteen hours using TLM.  Islet yield, viability, and functionality were significantly 
improved by both two-layer methods compared to UW solution alone. The human islet 
isolations with the two layer methods yielded about twice as many islets (2,659 ± 549 IEQ/g 
in the static TLM, 2,244 ± 557 IEQ/g in the original TLM) compared to the UW method 
(1,293 ± 451 IEQ/g). This study showed that the islet yield, viability, and in-vitro function 
were significantly improved by both TLM approaches with similar results. Since the static 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 
 
508 
TLM is easier and yields comparable results as the original method it has subsequently 
attained widespread use in clinical studies. In contrast, a larger study comparing the 
effectiveness of TLM vs preservation in UW solution alone reported no significant 
advantage in using TLM method (Caballero-Corbalan et al., 2007) 
Although this TLM is effective at oxygenating the pancreas, the organ is still a thick tissue 
with inner, non-accessed parts being exposed to a higher risk of damage. It has been 
hypothesized that the ductal system is thus especially susceptible to cold ischemic injury. 
This could result in the inability to properly perfuse collagenase (an essential reagent 
discussed later) by intraductal distention. By injecting cold preservation solution in the 
opposite direction through the main pancreatic duct, a majority of the inner spaces of the 
pancreas can be reached, preserving a greater number of islets for isolation, and allowing 
greater distention of the organ during collagenase injection (Matsumoto et al., 2002). 
Functionality results for islets isolated from pancreata receiving ductal injections of cold 
preservation solution were evaluated by an in-vivo assay, insulin secretion, and by viability 
testing. Ductal preservation significantly reduced the number of nonviable cells from 
around sixty percent to lower than twenty percent. Using this method, the insulin secretion 
ability of islets was also improved. The best determinant of islet quality is the in-vivo assay, 
which involves the transplantation of isolated islets under the kidney capsule of a diabetic 
nude mouse. This further confirmed that islets not preserved with ductal injection could not 
cure diabetic mice in any of the cases, whereas islets from pancreata perfused with UW 
solution showed a similar curative rate compared to islets from a fresh pancreas (Sawada et 
al., 2003).  
Protecting the pancreas from ischemic damage between procurement and processing is an 
important aspect of islet isolation. Although islets only constitute about 2-5% of the total 
pancreatic mass, they use over 10% of the organ’s blood supply. Therefore, sufficient 
oxygenation is important for islet function. Previous studies performed have demonstrated 
the ability of the two layer method and ductal preservation to yield higher numbers of 
improved quality islets. 
3.1.3 Collagenase 
Pancreas digestion is performed by injection of collagenase enzyme that cleaves the basic 
connective tissue. Successful human islet isolations hinge upon the quality of the 
collagenase used, which is the blade that cuts islets from the pancreas providing isolated 
islets. The types of collagenase traditionally used are derived from Clostridium histolyticum 
(Linetsky et al., 1997). Liberase HI is a blend of purified collagenases and protease that 
showed significantly higher islet yields when compared to crude collagenase extracts 
(Linetsky et al., 1997, Olack et al., 1999). Liberase HI provided the advantage of not only 
higher islet yields compared to crude collagenase, but also a reduction in contaminating 
enzymes and endotoxin. Despite these advantages, Liberase HI appeared to have 
inconsistencies between lots, and exhibited poor storage stability (Barnett et al., 2005). This 
enzyme blend further fell out of favor, because animal products such as bovine brain extract 
were used in the manufacturing process (Shimoda et al., 2010). Many centers turned to NB-1 
collagenase products (SERVA/Nordmark) in order to avoid the potential safety risks 
(Bucher et al., 2005, Shimoda et al., 2010). Results from many centers that used this enzyme 
are mixed in terms of generating islet yields and quality similar to those achieved by 
Liberase HI (Barnett et al., 2005; Yamamoto, 2007).   
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To show the further usefulness of an optimal collagenase, human pancreas isolations were 
performed by Balamurugan et al., (2010) with collagenase from VitaCyte (n=28) and 
Serva/Nordmark (n=30). The results of these isolations show that VIzyme produced 
significantly higher yields of islets. The final islet equivalent (IEQ) per gram of pancreas for 
VitaCyte enzyme versus Serva’s enzyme was 414,700±175,900 versus 213,400±152,400 with a 
p value of 0.002. Islet equivalent (IEQ) is the standard unit of measurement of islets and 
corresponds to a round islet with a diameter of 150 micrometers. From these isolation 
results, six clinical islet transplantations were performed. Two patients received islets 
isolated from Serva’s NB-1; one patient achieved normoglycemia for over 700 days and the 
other had evidence of graft failure on day 84. Of four patients transplanted with islets 
isolated using collagenase from VitaCyte, three were insulin independent for more than 350 
days. Although this clinical data is not conclusive, it does demonstrate that the utilization of 
VIzyme in islet isolation may prove beneficial to increasing islet yields. Further independent 
studies are warranted to validate such claims. 
3.1.4 Purification 
The final stage in the islet isolation process is purification to separate functional islets, from 
the contaminating acinar cells. The positive aspect of this process is a higher purity of islets 
to transplant; also the packed cell volume will be lower, decreasing the risk of an embolism 
or other risks associated with the islet infusion process. 
This separation process takes advantage of the different densities of acinar and islet cells, 
with acinar tissue being more dense than islets. However, one disadvantage is that the islet 
post-purification recovery is mostly decreased. The traditional gold standard for this process 
was the use of Ficoll, a heavy, multi-branched sugar that readily dissolves in water, based 
density gradient combined with semiautomated centrifugation with a COBE-2991 cell 
processor to achieve optimal results (Matsumoto et al., 2006). The centrifugation process can 
be mechanically stressful and damaging to islets; further the exposure to enzyme and 
endotoxin in the isolation can lead to apoptosis, inflammation, and attack by the immune 
system post-transplant. An alternative density solution, iodixanol, is a neutral iso-osmotic 
contrast solution used clinically in the imaging field. Iodixanol’s effect on the purification 
was studied along with the production of pro-inflammatory cytokines after islet isolation 
(Mita et al., 2010). Islets purified by iodixanol-based gradients yielded significantly lower 
levels of cytokines and chemokines when compared to Ficoll-based gradient solutions. The 
inflammatory molecules that were downregulated include interleukin-1 beta (IL-1ǃ), tumor 
necrosis factor-alpha (TNF-ǂ), interferon-gamma (IFN-Ǆ), IL-6, IL-8, macrophage 
inflammatory protein 1beta(MIP-1ǃ), and monocyte chemoattractant-1 (MCP-1). These 
cytokines are known to not only be pro-inflammatory, but some are also associated with 
apoptosis and necrosis. These results provide compelling data that iodixanol has a 
protective effect on islet preparations when used in density gradient purifications. 
Furthermore, Hering et al. (2005) have reported that islet preparations purified using 
iodixanol-based gradients were able to cure eight patients with a single transplantation.   
In the Edmonton protocol (2000), islets were transplanted immediately after isolation, 
without a period of culturing. Although this may cause attrition of islets, some argue that 
the culture period allows damaged ineffective islets to die off while permitting enough time 
for functional testing of islets prior to transplantation. Further, the culturing period could be 
used to pretreat the recipient or the islets themselves.  
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The culture of islets up to 48 hours pre-transplant has gained some popularity for several 
reasons. This culture time allows depletion of apoptotic islets and testing for sterility, 
microbiology, viability, and in vitro glucose stimulated insulin secretion response. The 
patient does not have to be rushed into a radiology suite to receive the infusion, but this 
time could allow for the start of an immune cell depleting induction therapy. 
Thus, the advances made in the area of islet isolation have been substantial over the past 
decade. The standardization to cGMP facilities, preservation with the two layer method and 
ductal injection method have all improved the preparative conditions for conducting an 
isolation. The optimization of the collagenase solution continues to improve islet yields after 
pancreatic digestion. By currently using iodixanol based density gradient solutions, the risk 
of apoptotic islet damage both after isolation and after transplantation has been reduced by 
the lowering of inflammatory cytokines. These improvements have led to higher yields and 
islets with greater functionality, which provides transplant recipients a greater chance at 
achieving insulin independence. 
3.2 Advances in immunosuppression to prevent islet graft rejection 
Although it is difficult to obtain islet preparations of an adequate quantity and quality for 
transplantation, it is also very difficult to protect and maintain the allogenic islet function 
after transplantation. There are several aspects of the immune system that prevent the long 
term survival of islet cells. The first reaction encountered by islets is the instant blood 
mediated inflammatory response (IBMIR), primarily mediated by the innate immune 
system which leads to islet destruction (Bennett et al., 1999). Islets surviving this initial, 
short term inflammatory response are later subjected to targeting of autoimmune and 
alloimmune responses. The alloimmune response is primarily directed against mismatched 
HLA. The autoimmune response which already exists in type 1 diabetic recipients, being the 
source of the pathogenesis of the disease and is specifically reactive to beta cell markers such 
as glutamic acid decarboxylase (GAD65) and islet cell antigen (ICA) (Shapiro et al., 2003). 
Immunosuppressive regimens for islet cell transplant recipients must counter these aspects 
of the whole immune response for improved graft survival. 
Immunosuppression after islet transplantation is comprised of two phases namely induction 
and maintenance therapies. The induction phase is characterized by anti-inflammatory 
drugs and monoclonal or polyclonal antibodies that deplete immune cells (anti-CD3 and 
anti-thymocyte globulin) or prevent T-cell activation (anti-IL-2 receptor) (Stock & Bluestone, 
2004; Matsumoto et al., 2011). The maintenance drug regimen is focused on suppression of 
T-cells by various strategies including calcineurin inhibitors such as tacrolimus, and 
cyclosporine. Other drugs such as mycophenolate mofetil (MMF) have also been used with 
good outcomes. 
In the early days of islet transplantation, drugs administered to counter the immune system 
were found to be toxic to islet cells (Stock & Bluestone, 2004). Beta cells naturally have lower 
levels of anti-oxidant enzymes, which put them at an increased risk. Further, the hepatic 
graft site puts islets in contact with blood that has higher concentrations of the 
immunosuppressive drugs, increasing any negative side effects. The advent of the 
Edmonton protocol demonstrated successful islet transplantations, with a part of the 
accomplishment being attributed to minimizing calcineurin inhibitors and a steroid-free 
induction process.  
www.intechopen.com
 
Beta Cell Replacement Therapy 
 
511 
3.2.1 Induction therapy 
The first stage of treatment for islet transplantation is the induction therapy that attempts to 
reduce the inflammatory effects of the short term immune system. It has been estimated that 
during the initial phase after transplant, as much as 50 to 60% of the islets graft is lost due to 
IBMIR (Bennett, 1999). Within as little as five minutes, natural IgG and IgM lead to 
complement activation starts to attack it by creating perforin complexes that lead to cell lysis 
(Tiernberg, 2008). Another significant physiological change involved in IBMIR is the 
dramatic, rapid increase in cytokine levels such as IL-2, TNF-ǂ, IL-1ǃ, and IFN-Ǆ. Due to 
diabetogenic effects glucocorticoids are avoided in the immunosuppressive regimens 
turning to newer alternatives (Shapiro et al., 2000). An alternative to steroids is daclizumab, 
a humanized monoclonal antibody with specific affinity to the IL-2 receptor. This receptor 
on T-cells is responsible for the main activation pathway, which triggers an immune 
response against beta cells.  
Thymoglobulin has become a popular agent for the reduction in host T-cells (Finke, 2009). 
This thymoglobulin is a polycolonal antibody that targets T-cells, thus depleting the cells 
required to mount a specific response to islets even before they enter the body. 
Another T-cell depleting agent used for induction therapy is alemtuzumab (Maggliocca, 
2006). Alemtuzumab is a monoclonal antibody against CD52, which is a marker of mature 
lymphocytes. One specific complication is that it increases the chance of infections while 
also increasing the possibility of reactivation of cytomegalovirus. 
Another target of induction therapy includes the proinflammatory cytokine response. Our 
group and others have shown that IL-1ǃ plays an important role in the onset of T1D. 
Additionally TNF-ǂ blockage was shown to significantly improve the clinical outcome of 
patients based on the collaborative islet transplant registry (CITR) database (CITR Report 
2009). To abrogate the inflammatory effects of these cytokines a combined treatment of 
eternacept and anakinra was used for induction therapy (Matsumoto, 2011). Etanercept is a 
TNF-ǂ inhibitor, acting as a decoy receptor and blocking the true effect of TNF. Anakinra is 
an IL-1 receptor antagonist blocking the activity of IL-1ǃ. This anti-inflammatory response 
was combined with thymoglobulin for the induction therapy. All patients undergoing this 
therapy were able to achieve insulin independence following a single islet infusion. Gene 
microarray analysis was performed on blood samples taken within the first week post-
transplant. The results of the gene microarray demonstrated that genes related to cytotoxic T 
cells were repressed; however, there was upregulation seen in inflammation and neutrophil 
related genes. This suggests that there may be alternative inflammatory cytokines and 
agents that may be relevant to the immediate immune reaction.  
3.2.2 Inhibition of NF-kB to prevent inflammation 
Instead of trying to target all of the extracellular agents that might cause an inflammatory 
reaction, an effort was made to find and inhibit a downstream signaling protein that is 
activated by pro-inflammatory cytokines. Nuclear factor kappa-light-chain-enhancer of 
activated B-cells (NF-κB) is a protein that regulates transcription of several sequences of 
DNA and is activated through a canonical pathway by inflammatory cytokines (Hawiger, 
2001). This led us to believe that inhibition of NF-κB would inhibit the collective effects of 
circulating cytokines.  
An inhibitor of NF-κB activation was found in traditional eastern medicine from the plant 
Withania somnifera extract called Withaferin A, WA (Kaileh et al., 2007). Withaferin A is a 
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steroidal lactone that prevents the phosphorylation and subsequent degradation of inhibitor 
of kappaB (IkB), which sequesters NF-κB in the cytoplasm. Studies by Peng et al. (2010) 
showed that RNA transcripts of inflammatory cytokines and chemokines such as IP-10 
(CXCL10), RANTES (CCL5), MIP-1 (CCL4), and MCP-1 (CCL-2) were upregulated in 
human islets in the presence of cytokines. However, WA was able to inhibit this effect. WA 
was not shown to decrease islet viability or functionality, while simultaneously inhibiting 
the inflammatory response. This result demonstrates that careful regulation of NF-κB can 
have a beneficial effect for islet transplantation by preventing the effects of cytokine induced 
damage. 
Another NF-κB inhibitor was found to improve intraportal islet transplantation by IKK-ǃ 
inhibition (Chen et al., 2011). This study showed higher retention of insulin independence in 
a xenogenic model when a proprietary NF- κB inhibitor drug was injected once, thirty 
minutes before the transplantation. The primary anticipated effect of NF- κB inhibition is on 
the IMBIR reaction which is more easily studied in a syngenic model, where the only source 
of graft failure is IBMIR rather than a specific adaptive immune response.  
3.2.3 Maintenance therapy 
The purpose of the maintenance therapy is to suppress the specific alloimmune and 
autoimmune responses mediated by T and B lymphocytes. The drugs typically used for this 
purpose include Prograf, Rapamycin, MMF, and blockers of co-stimulation. Several 
combinations of these therapeutic agents have been attempted in clinical islet 
transplantations to increase the longevity of the graft while minimizing the beta cell toxicity 
and patient related adverse events. 
The types of immunosuppression traditionally used for transplantation are the calcineurin 
inhibitors tacrolimus and cyclosporine, but often these agents were associated with toxic 
effects for beta cells (Drachenberg, 1999). Tacrolimus is an immunosuppressant that was 
found to inhibit NF-AT activation. The original molecule was found in the fermentation of a 
soil sample containing the bacterium Streptomyces tsukobensis (Pritchard, 2005). Tacrolimus 
inhibits the activation of NF-AT and its translocation to the nucleus by forming a complex 
with the immunophilin FKBP12 to inhibit the activation of calcineurin and subsequent T-cell 
activation (Liu, 1991). This action also leads to the arrest of the cell cycle, preventing it from 
moving from the G0 stage to the G1 stage; thus cellular proliferation is prevented. 
Cyclosporin acts in a similar way as tacrolimus, binding to cyclophilin to prevent 
calcineurin mediated dephosphorylation of NF-AT; however tacrolimus exhibits greater 
potency with fewer harmful side effects compared to cyclosporine. 
Although the calcineurin inhibitors have been effective at inhibiting rejection in solid organ 
transplant, they have also been associated with the onset of diabetes mellitus. This is a 
serious implication for a transplantation procedure trying to prevent this very condition. 
This side effect was histologically analyzed in solid pancreas transplants for patients  
receiving either tacrolimus or cyclosporine in a randomized fashion (Drachenberg, 1999). 
Sectioned biopsy samples from 1 to 8 months post-transplant revealed cytoplasmic swelling, 
vacuolization, apoptosis and irregular insulin staining of islets for patients receiving both 
drugs. Although islet cell damage was more frequent for patients receiving tacrolimus 
versus cyclosporine (10/13 versus 5/13 respectively), it was not significantly different.  
Since tacrolimus is more effective with less side effects, it is used more often. But as this 
study shows it should be administered in low doses to prevent beta cell toxicity.  
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Reference 
# of 
Patients
Insulin 
Independence 
(%) 
Long Term 
Follow Up 
Immunosuppression 
Shapiro et al., 
2000 
8 100% 18% at 5yrs 
Daclizumab (Dac), Rapamycin 
(Rap), Tacrolimus (Tac) 
Noguchi et al., 
2005 
5 60% NA Basiliximab, Rap, Tac 
Ryan et al., 2005 65 90% 
70% at 1yr 
10% at 5yrs 
Dac, Rap, Tac 
Toso et al., 2006 8 100% 
71% at 1 & 2 
yrs 
Dac, Rap, Tac 
Vantyghem et 
al., 2009 
5 60% 
20% 
After 1yr 
ATG, Rap/ Tac 
14 100% 
71% at 1 yr 
57% at ~3yr 
Dac, Rap, Tac 
Froud et al., 
2008 
3 66% 
66% 
After 2 yr 
Alemtuzumab, Rap/Tac (3 
mo.), then Rap/MMF 
Matsumoto et 
al., 2010 
3 100% 53±7 days 
ATG, Tac, MMF, Enteracept, 
Anakinra 
Posselt et al., 
2010 
3 100% 40±4 days Dac, Rap, Tac, Enteracept 
8 100% 
75% at 1 yr* 
38% at 2yrs* 
ATG, Efalizumab, Rap, MMF 
Shapiro et al., 
2010 
12 100% 83% at 3yrs Alemtuzumab, Tac, MMF 
Hering et al., 
2011 
16 88% 38% Dac, Rap/ Tac 
8 100% 63% at 1 yr 
ATG, Dac, Enteracept, MMF, 
Rap, Tac 
*These numbers are limited, because the drug being tested, Efalizumab, was withdrawn from the 
market during treatment. 
Table 1. Summary of Clinical Islet Transplantation Outcome.  
Rapamycin (sirolimus) has a different mechanism of action and side effects compared to the 
calcineurin inhibitors (Pritchard, 2005). Although rapamycin binds to FKBP12 in a similar 
mechanism like tacrolimus, it does not inhibit calcineurin, rather the complex inhibits 
mTOR (mammalian Target Of Rapamycin). This inhibits the second phase of T-cell 
activation, whereas tacrolimus and cyclosporine inhibit the first phase. So rapamycin also 
inhibits signal transduction leading to IL-2 production and clonal proliferation, and since it 
affects a different part of T-cell activation it can be used synergistically with calcineurin 
inhibitors. One of the side effects associated with this drug is oral ulcers that make ingestion 
of food difficult. Rapamycin is thus a potential alternative or adjunct to calcineurin inhibitor 
mediated T-cell inhibition. 
Another widely used immunosuppressant is mycophenolate mofetil, MMF, which prevents 
B and T-cell proliferation (Ransom, 1995). This is the first of two enzymes responsible for the 
production of guanosine monophosphate from inosine monophosphate; lymphocytes are 
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particularly dependent on this pathway for the subsequent synthesis of GDP, GTP, and 
dGTP. The reduction of GTP and dGTP levels in lymphycytes results in a decreased ability 
to perform DNA synthesis and GTP dependent metabolism. Some of the adverse events 
associated with this drug include nausea, infections, leucopenia, and anemia. This 
alternative mechanism of specific immune system suppression has led to the widespread 
use of MMF in combination with tacrolimus or sirolimus. One such study was performed 
recently by Shapiro et al. in 2010 by combining MMF with tacrolimus for maintenance with 
alemtuzumab induction. This study was compared to the original Edmonton protocol which 
used daclizumab for induction and a combination of tacrolimus and sirolimus as seen in 
Table 1. It was hypothesized that MMF would be better tolerated than high dose sirolimus. 
Of the 12 patients with completed islet infusions, 83% (10/12) are still insulin independent 
at 36 months, whereas two patient’s grafts failed after removing immunosuppressants due 
to infections. The mechanism underlying this tolerance seemed to be linked to a unique 
donor specific IL-10 regulated immune response, leading to improved insulin independence 
rates.  
There have also been several antibody mediated approaches to preventing T-cell activation by 
blocking costimulation. This approach enabled a calcineurin inhibitor and gluococorticoid free 
immunosuppression regimen; the antibody used was efalizumab (anti-LFA 1 antibody) 
(Posselt et al., 2010). These antibodies were used as supplements to sirolimus/MMF 
maintenance therapy. The result was that 5/5 of patients receiving eflizumab achieved insulin 
independence with several maintaining graft function for over a year. Unfortunately, this 
therapy cannot be continued, because efalizumab was withdrawn from the market by the FDA 
in mid 2009 (Posselt et al., 2009). Despite the progress made, any use of immunosuppressants 
will slow the widespread applicability of islet transplantation, since the cost benefit analysis of 
immunosuppression must be compared to insulin therapy alone.  
3.3 Xenogenic porcine islets for transplantation 
Even if all pancreatic islet cell transplantations became successful and only required one 
pancreas to achieve insulin independence, there would still be an insufficient number of 
pancreata to treat all type 1 diabetic patients. There are approximately 7,000 pancreases 
available for donation in the United States per year, but diabetes milletus affects as many as 
3 million people in the United States and as many as 16 million people worldwide. This 
shortage in human islet cells from organ donor sources has led to a search for alternative 
sources (Hering & Walawalkar, 2009). One source that has been identified is porcine islets, 
which secrete physiologically functional insulin but can be highly immunogenic to humans 
and carry a risk of cross-species infection by pig endogenous retroviruses. 
A particular surface epitope that has led to increased xenoreactivity is galactose-1,3- 
galactose (Rayat et al., 1998; Korbutt et al., 1997). Through genetic engineering of pig herds, 
a knockout animal which lacks this epitope has been successfully bred (Puga Yung et al., 
2009). However kidney transplantation results using this animal have shown only modest 
gains. 
Another fear of porcine islet transplantation is that pig endogenous retrovirus (PERV) could 
be transmitted from the porcine islets transplanted into the human recipient. Although pigs 
can be bred in pathogen-free facilities that shields them from contracting microbes that can 
be transmitted, PERV is integrated into the genome and the risk of infection cannot be so 
easily removed. When recipients are immunosuppressed, porcine cytomegalovirus or pig 
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lymphotrophic herpes virus are common infections that can be activated under 
immunosuppression. There have been conflicting reports of PERV manifesting in non-obese 
diabetic mice transplanted with pig islets. For humans, sensitive detection techniques such 
as quantitative polymerase chain reaction or immunoblotting assays for PERV proteins. 
With respect to clinical trials of xenotransplantation, there is little evidence of transmission 
of xenogenic endogenous virus transmission (Elliott et al., 2005; Garkavenko et al., 2011).  
Porcine islets have even been used in two clinical trials of islet transplantation, one in 
Mexico (Valdes-Gonzales et al., 2005) and one in New Zealand (Garkavenko et al., 2011). 
The Mexico trial involved transplantation of collagen generating devices embedded with 
islet and sertoli cells into twelve juvenile type 1 diabetic patients. The purpose of the sertolli 
cells was to prevent the action of the immune system. This procedure did not produce long 
term insulin independence, but glycemic control was improved along with positive porcine 
C-peptide in patient urine during long term follow-up.  
A second noteworthy clinical trial is being performed in New Zealand using alginate 
encapsulated neonatal porcine islets transplanted into the peritoneal cavity of type 1 
diabetic patients. The pigs used were raised in pathogen-free facilities with a donor herd 
free from conventional pathogens and non-transmittable PERV. This unique lack of 
exposure to viruses is a characteristic of these pigs which were raised on the island of New 
Zealand with limited exposure to foreign diseases. In terms of xenogenic related infection, 
zoonosis has been rigorously monitored with no evidence of cross-species infection. Again, 
no patients became insulin independent, but there was a significant reduction in 
hypoglycemic unawareness episodes. This encapsulation method demonstrates the 
usefulness of immunoisolation in islet transplantation (Elliott RB, 2011). 
Porcine islets have been used to explore alternative transplant sites, since blood in the portal 
vein of the liver often contains higher concentrations of immunosuppressants and other 
toxins, while containing low concentrations of oxygen. Areas of porcine islet transplantation 
into non-human primates include intraperitoneum, renal subcapsule, subcutaneous, the 
omentum pouch, and the mesentery (Hering & Walawalkar, 2009). The efficacy of each 
transplant site is difficult to determine as various immunosuppressive therapies were used 
in addition to encapsulation and the use of a subcutaneous mono-layer device. These large 
animal studies have shown some success demonstrating the ability in some cases to create 
insulin independence with immunosuppressants. Finally, genetic modification of donor pigs 
permits the upregulation of certain genes that would have cytoprotective or 
immunomodulatory effects to improve engraftment and reduce the effect of the immune 
response. 
3.4 Islet Immunoisolation 
The leading strategy to reduce or eliminate the most risky aspect of islet transplantation, 
namely immunosuppression drugs, is immunoisolation. To protect islets from the 
recognition of the immune system, two strategies have been used, specifically encapsulation 
and surface modification (Wilson & Chaikof, 2007) as shown in Figure 1. Encapsulation 
involves, as its name suggests, enclosing an islet in a capsule that is impermeable to the 
immune system. These capsules are typically composed of agarose or poly(vinyl alcohol) 
alginate. The capsules must have defined pore sizes that allow the influx of glucose as well 
as the secretion of insulin, while simultaneously preventing intrusion by complement or 
antibodies. These modifications also allow drug delivery by covalent attachment of anti-
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thrombogenic or immunosuppressive agents, which would be applicable to both human 
allotransplantation or xenotransplantation. 
3.4.1 Encapsulation 
The encapsulation method is limited by bioincompatibility and biodegradation of the 
materials in addition to hypoxic damage to the islets (Lee & Byun, 2010). Further there is the 
practical limitation of size; the typical islet diameter of 150 µm is often increased by as much 
as 5 fold, leading to a volume increase greater than 100 fold. Since more than 500,000 islet 
equivalents are now required to cure diabetes (~10mL islet pellet volume), that volume 
would be increased to over 1 liter with encapsulated islets. This would exclude 
transplantation into the portal vein of the liver, because this volume of islets would 
significantly increase the risk of portal vein thrombosis and other bleeding complications. 
Thus, alternative sites of injection such as subcutaneous, intraperitoneal, or intramuscular 
have to be validated. However, this technique still would have the issue of incomplete 
encapsulation or variable number of islets entrapped.  
3.4.2 Surface modification  
An alternative to macroencapsulation is surface modification, which uses the islet surface as 
the scaffolding upon which to build protective barriers. One such surface modification 
method is conformal coating, which uses derivatives of the molecule diacrylate (Cruise et 
al., 1999) Conformal coating uses the islet surface to deposit or chemically grow a protective 
barrier without as large of a size increase; the final diameter is only increased by 30 to 50µm 
in human and porcine islets.  
 
 
Fig. 1. Immunoisolation methods for islets from largest size to smallest increase in size. 
Another study demonstrated the use of proteins as a protective barrier by reacting a 
disuccinimidyl bifunctional poly-ethylene glycol (PEG) molecule on one side with the islet 
surface and the other side to albumin (Xie et al., 2005). Another method of surface 
modification is PEGylation, which attaches long chains of PEG, a hydrophilic, biologically 
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inert, flexible polymer chain. This method of surface modification has been applied 
previously to the immunoisolation of red blood cells to mask the ABO surface antigens from 
host antibodies (Scott et al., 1997; Murad et al., 1999). These experiments show that surface 
PEGylation of islets can be accomplished successfully without loss in viability or 
functionality. One of the main advantages of PEGylation to islets is that there is no 
significant size increase like that associated with macroencapsulation. There is only a 
microscopic increase in size, because the PEG conjugated islets (PEGylated islets) are 
modified at the molecular level. The traditional and most widely used PEGylation technique 
applied uses a succinimidyl functionalized PEG (N-hydroxysuccinimide, NHS), which 
reacts to surface amine groups on the islet surface (Lee et al., 2007). However, there are 
several other surface moieties that can be targeted by chemical modification. There have 
been studies that investigate PEGylation by targeting the lipid membrane (Teramura et al., 
2007), and surface sugars (Wilson et al., 2010). This same study also analyzed optimization 
of surface modification by varying reaction time and concentration of the functionalized 
PEG; the new oxidative method was even combined with the traditional NHS method. 
However there remain more surface modification targets available such as disulfide bridges; 
even photochemical techniques that have been applied to protein linkage of tissue (Zhang et 
al., 2004). Another poorly studied aspect of islet surface modification is in relation to the 
longevity of the modification methods. The islet surface is a dynamic environment, with 
constant turnover and regeneration of the cell membrane. Almost all of the PEGylation 
techniques mentioned only look at the uniformity and quantity of the PEG immediately 
after modification. If PEG is supposed to protect islets from the immune system, it should be 
robust and remain for a long time in order to protect islets from T-cell mediated rejection. 
Biologically active agents that have been attached to islet surfaces include heparin, activated 
protein C, urokinase, or thrombomodulin (Cabric et al., 2007; Contreras et al., 2004; 
Teramura & Iwata, 2008; Stabler et al., 2007). Development of a standardized analytic 
method that determines PEG density/ islet (size adjusted) and uniformity over a long time 
period would provide the ability to compare surface modification chemistries and optimize 
PEGylation reactions. 
4. Beta cell regeneration 
Development of type 1 diabetes is a consequence of loss of functional beta cell mass. Hence 
the objective of many therapeutic approaches to treat T1D is to restore beta cell mass 
sufficient to maintain normoglycemia. Results from the clinical islet transplantation trials 
have reinforced this concept. In a healthy individual, the beta cells lost are constantly 
replenished by beta cell neogenesis through mechanisms which are not clearly understood. 
Beta cell mass is maintained and regulated in response to pharmacological and nutritional 
stimuli which include glucose, insulin, epidermal growth factor (EGF), gastrin and glucagon 
like peptide (GLP-1). Physiological stimuli such as pregnancy, obesity and pancreatic tissue 
damage also significantly regulate beta cell mass. Beta cell development in pancreas is 
regulated by the hierarchical expression of a specific complement of transcription factor 
proteins (Edlund H, 1998). Originating from cells expressing homeodomain transcription 
factor PDX1 (pancreatic/duodenal homeobox 1) and repressing sonic hedgehog, both 
endocrine and exocrine cells of the adult pancreas arise from endodermal cells expressing 
PDX1 and Ptfla. Fibroblast growth factor family of proteins stimulate the proliferation of 
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progenitor cells in addition to specific stimuli from mesenchymal cells. Formation of beta 
cells is further driven by the transient expression of Pax4 in ngn 3-expressing cells. Beta cell 
expansion begins when transcription factor complement being driven by PDX1, Pax6, 
Nkx2.2 and Nkx6.1 (Edlund H, 1998).  
In the adult pancreas, beta cell replication is a key phenomenon for the emergence of 
neogenic beta cells, however, the rates of beta cells replication is extremely low. The origin 
of neogenic beta cells is unclear. Several possibilities including differentiation of pancreatic 
stem cells or ductal or acinar cells are proposed. The plasticity of adult pancreatic cells is 
thought to play an important role in the neogenesis of beta cells. Attempts to 
transdifferentiate liver cells or intestinal K cells in insulin producing beta cells have also 
been reported through coordinated alteration in gene expression and cellular phenotype 
(Campbell and Macfarlane, 2007). A number of hormones and growth factors have been 
shown to stimulate renewal of beta cells which include GLP1 analog, EGF and gastrin. GLP1 
is an incretin hormone produced by L-cells of the intestine. GLP-1 augments insulin 
secretion (Melloul et al, 2002). GLP-1 binds to specific GLP-1 receptor and activates 
intracellular signaling events involving protein kinase A and changes in cyclic AMP levels. 
GLP-1 released from the intestinal L-cells is rapidly degraded by the dipeptidase enzyme 
DPPIV. Inhibitors of DPPIV are now increasingly used to control glucose levels in type 2 
diabetic patients. GLP-1 has also been shown to increase PDX1 gene expression in ductal 
cells during the regeneration of pancreas (Sharma et al., 1999). A similar line of action has 
been proposed for thiazolidinediones in the enhancement of neogenic beta cell function 
through activation of nuclear receptor peroxisome proliferator activator gamma (PPAR) 
(Richardson et al., 2006) 
5. Stem cells 
Stem cells have the potential to undergo symmetric cell divisions as well as asymmetric cell 
divisions for lineage commitment such as differentiation into insulin-producing cells. Stem 
cells may offer an important and unlimited source for beta cell replacement. Stem cells can 
be broadly classified as embryonic (ESC) or adult (ASC) stem cells. ESCs are isolated from 
the blastocyst which is formed during embryonic development while ASCs are detected 
within tissues (Fuchs et al., 2004). Both cell types are capable of commitment to specific cell 
lineages. ESCs exhibit greater plasticity (pluripotency) in terms of differentiation into almost 
any cell type, however, ASCs are limited in their commitment to repertoire of cell types 
(multipotency).  
ESCs offer a potential source for beta cell neogenesis. However, it is difficult to maintain 
human ESCs in an undifferentiated state under in vitro culture conditions. The molecular 
mechanisms that derive ESCs into insulin producing are not clearly defined yet; however, 
nutrients, oxygen and other growth factors have been shown to play a critical role (Smith, 
1991). Only a small percentage (<2%) of ESCs have been shown to spontaneously 
differentiate into insulin producing cells, thus limiting their clinical application. Several cell 
culture strategies have been proposed to increase the percentage of insulin producing cells 
from ESCs. Unfortunately the amount insulin obtained with these strategies is extremely 
low when compared to insulin content of the beta cells of pancreas (Roche and Soria, 2006). 
Despite their limited capacity for proliferation ASCs offer the advantage of immune 
compatibility in the development of beta cell replacement therapies. However, ASCs may 
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still be targeted by the autoimmune response. ASCs isolated from pancreatic tissue have 
been shown to differentiate in vitro into islet-like structures (Bonner-Weir et al., 2000; 
Ramiya et al., 2000) lending support to the notion that ductal cells may serve as islet 
progenitors. Culture of ductal cells isolated from human pancreas under specific conditions 
resulted in islet-like clusters that exhibited islet-specific hormones and transcription factors. 
Further, these islet-like clusters showed increased insulin response to glucose challenge. In 
contrast, Dor et al., (2004) have proposed that beta cell neogenesis in adult pancreas is solely 
derived from replication of pre-existing beta cells and not from stem cell precursors. Thus 
identification of true islet progenitors and the mechanisms that differentiate stem cells into 
normal insulin producing beta cells are still under progress.  
In summary, great strides have been made in development of a physiological treatment for 
insulin-dependent diabetes. Four broad types of approaches as shown in figure 2 are 
currently being pursued to find a cure for this increasing health hazard. While some of these 
approaches have progressed well enough to find clinical application, others are lagging 
behind due to technological deficiencies. Transplantation of allogenic pancreas organ or 
 
 
Fig. 2. Opportunities and Challenges to beta cell replacement therapies. Green colored 
arrows indicate opportunities and the red colored hammer indicates challenges. 
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isolated pancreatic islets have shown the most progress in terms of clinical application and 
are currently limited by the lack of suitable organ supply and islet-friendly 
immunosuppression. Transplantation of pig islets could overcome the hurdle of donor 
organ shortage, but the safety and efficacy of such xenotransplantation remains to be 
determined. Immune isolation of allogenic and xenogenic islets will significantly prolong 
the survival of transplanted islets and also prevent the harmful effects of host immune 
response. Optimization of encapsulation technologies to support islet cell function in the 
long term is not fully developed yet. Replacement of beta cells derived from alternative 
sources such as stem cells has the potential to offer unlimited supply of beta cells and is 
currently receiving greater attention from the research community.  
6. Conclusion 
Incidence of diabetes is increasing at an alarming rate in different populations all over the 
world. Diagnosis of T1D is also following this increasing trend, constituting 5-10% of the 
total diabetes cases. Exogenous insulin therapy is proving to be adequate for majority of 
T1D patients; however, for “brittle” T1D patients control of blood glucose levels is very 
difficult using this treatment. Transplantation of whole organ pancreas is an established 
procedure to restore beta cell mass to attain normoglycemia. Transplantation of isolated 
islets has seen a tremendous growth in the past decade in terms of the number of transplant 
recipients, improvement in the islet isolation methodologies and post-transplant graft 
survival and function. Due to limited supply of qualified pancreata for transplantation, 
other approaches to replace beta cells are gaining attention. Pig islets are an attractive option 
in terms of abundant supply and physiological similarity of insulin despite the possible risk 
of infection. Beta cell replacement using regeneration of stem cells or other cell types have 
shown promising results, however, are too far away from clinical application. Importantly, 
immune isolation of transplanted islets or beta cells using macro- or micro-encapsulation 
technology may significantly improve the current outcomes of cell-based therapy.    
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